Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of GZR18 in Healthy Subjects
NCT05328726Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing GZR18 with Placebo (2 arms). Primary endpoint: Dose limiting toxicity up to 31 days. Started Mar 2022; status: completed.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05328726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328726.